Lixisenatide
approvedAlso known as: Adlyxin, Lyxumia
**Mechanism of Action** Lixisenatide is a synthetic, short-acting GLP-1 receptor agonist derived from exendin-4, with a 39-amino acid sequence modified to resist DPP-4 degradation. It binds with high affinity to the GLP-1 receptor, stimulating glucose-dependent insulin secretion and suppressing glucagon release. Its short half-life (~3 hours) and pronounced effect on delaying gastric emptying distinguish it from longer-acting GLP-1 agonists, reducing postprandial glucose excursions primarily through slowed nutrient absorption rather than sustained insulinotropic action. **Key Research Findings** Clinical trials (e.g., GetGoal series) demonstrated significant reductions in HbA1c (0.5–0.9%) and fasting/postprandial glucose in type 2 diabetes, with a low risk of hypoglycemia. Lixisenatide also reduced body weight by 2–3 kg over 24 weeks. Cardiovascular outcome trials (ELIXA) showed neutral effects on major adverse cardiac events but a trend toward reduced heart failure hospitalizations. Notably, its gastric-emptying delay is more pronounced than with longer-acting GLP-1 agonists, leading to higher rates of nausea (20–30%) and vomiting (5–10%). **Clinical Relevance** Approved as adjunct to diet/exercise for type 2 diabetes, lixisenatide is particularly suited for patients needing strong postprandial glucose control. Its short duration allows flexible dosing (once daily) and rapid offset if adverse effects occur. However, it is contraindicated in gastroparesis and requires caution with medications dependent on gastric absorption. Lixisenatide is not recommended as first-line therapy due to modest HbA1c reductions compared to longer-acting GLP-1 agonists. For research purposes only — not medical advice.
Key data
C215H347N61O65SResearch & studies
Lixisenatide slowed motor disability progression at 12 months compared to placebo (difference 3.08 points on MDS-UPDRS part III).; After a 2-month washout, motor scores remained better with lixisenatide (17.7 vs 20.6).; Secondary end points did not differ substantially between groups.; Gastrointestinal side effects were common: nausea in 46% and vomiting in 13% of lixisenatide recipients.
GLP-1 agonists promote weight loss in both diabetic and non-diabetic patients.; These medications improve hyperglycemia, insulin sensitivity, and blood pressure.; Cardio-metabolic and renal protective effects are observed with long-term use.; The review outlines indications, contraindications, and precautions based on long-term follow-up studies.
GLP-1 RAs are available in twice-daily, once-daily, once-weekly, and oral formulations, with long-acting agents providing better fasting glucose and HbA1c control.; All GLP-1 RAs share mechanisms: enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce calorie intake and body weight.; Cardiovascular outcome studies since 2016 show GLP-1 RAs effectively prevent major adverse cardiovascular events, especially in patients with atherosclerotic disease.; GLP-1 RAs are recommended as first injectable therapy for type 2 diabetes, with potential benefits for renal complications and exploration in other diseases.
Frequently asked questions
What is Lixisenatide?
**Mechanism of Action** Lixisenatide is a synthetic, short-acting GLP-1 receptor agonist derived from exendin-4, with a 39-amino acid sequence modified to resist DPP-4 degradation. It binds with high affinity to the GLP-1 receptor, stimulating glucose-dependent insulin secretion and suppressing glucagon release. Its sh
How does Lixisenatide work?
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
What is the research status of Lixisenatide?
Lixisenatide is currently classified as approved, with 710 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Lixisenatide?
Lixisenatide has a molecular weight of approximately 4858 g/mol (formula C215H347N61O65S).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.
Build on Lixisenatide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key